Injectable buprenorphine formulation
The present invention provides an injectable liquid formulation comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention further provides a controlled-release composition formed by administration of such an injectable liquid composition to a, preferably human, subject. The invention also provides a method of administration of buprenorphine to a subject comprising injecting such a liquid composition and a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and/or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and/or cocaine withdrawal by injecting such a liquid composition.
1. An injectable liquid formulation having a total weight and comprising:
a) a lipid controlled-release matrix comprising at least 80% at least one triglyceride;
b) at least one oxygen containing organic solvent; and
c) 50-600 mg of at least one active agent selected from buprenorphine and at least one salt thereof, calculated as buprenorphine free base.
2. The injectable liquid formulation of claim 1 , wherein the injectable liquid formulation comprises at least 16% by weight of the at least one active agent, based on the total weight of the injectable liquid formulation.
3. The injectable liquid formulation of claim 1 , wherein the component a) comprises at least 90% of the at least one triglyceride.
4. The injectable liquid formulation of claim 1 , wherein the component a) comprises at least 95% of the at least one triglyceride.
5. The injectable liquid formulation of claim 1 , wherein the component a) further comprises:
i) at least one neutral diacyl lipid;
ii) at least one tocopherol; and/or
iii) at least one phospholipid.
6. The injectable liquid formulation of claim 1 , wherein the component a) comprises 10 to 60 wt. % of the total weight of the injectable liquid formulation.
7. The injectable liquid formulation of claim 1 , wherein the component a) comprises at least 50 wt. % of at least one triglyceride comprising C16 to C20 acyl groups having zero, one, and/or two unsaturations.
8. The injectable liquid formulation of claim 1 , wherein the component a) comprises at least 60 wt. % of at least one triglyceride comprising C16 to C18 acyl groups having zero, one, and/or two unsaturations.
9. The injectable liquid formulation of claim 1 , wherein the component b) is present at 15 to 50 wt. % based on the total weight of the injectable liquid formulation.
10. The injectable liquid formulation of claim 1 , wherein the component b) comprises at least one amide and/or at least one sulphoxide.
11. The injectable liquid formulation of claim 10 , wherein the component b) comprises N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), or a mixture thereof.
12. The injectable liquid formulation of claim 1 , wherein the injectable liquid formulation is in ready-to-administer form.
13. The injectable liquid formulation of claim 1 , wherein the injectable liquid formulation has a viscosity of 20 to 600 mPas at 20° C.
14. The injectable liquid formulation of claim 5 , wherein the lipid controlled-release matrix comprises the at least one phospholipid, and wherein the ratio of the at least one triglyceride:at least one phospholipid (w/w) in the lipid controlled-release matrix a) is in the range of 90:10 to 100:0.
15. The injectable liquid formulation of claim 5 , wherein the lipid controlled-release matrix comprises the at least one phospholipid, and wherein the level of the at least one phospholipid in the injectable liquid formulation as a whole is less than 8 wt. %, based on the total weight of the injectable liquid formulation.
16. The injectable liquid formulation of claim 1 , wherein the component a) comprises greater than 90% of the at least one triglyceride, and wherein the component a) comprises at least 50 wt. % of at least one triglyceride comprising C16 to C20 acyl groups having zero, one, and/or two unsaturations.
17. The injectable liquid formulation of claim 1 :
wherein the component a) constitutes 10 to 70 wt. % of the total weight of the injectable liquid formulation,
wherein the component b) constitutes 10 to 60 wt. % of the total weight of the injectable liquid formulation, and
wherein the component b) comprises at least 50% N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), and/or a mixture thereof.
18. The injectable liquid formulation of claim 1 :
wherein the component a) constitutes 10 to 60 wt. % of the total weight of the injectable liquid formulation,
wherein the component b) constitutes 15 to 50 wt. % of the total weight of the injectable liquid formulation, and
wherein the component b) comprises at least 70% N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), and/or a mixture thereof.
19. The injectable liquid formulation of claim 1 :
wherein the component a) constitutes 15 to 64 wt. % of the total weight of the injectable liquid formulation,
wherein the component a) comprises at least 90% of the at least one triglyceride,
wherein the component b) constitutes 20 to 45 wt. % of the total weight of the injectable liquid formulation, and
wherein the component b) comprises at least 80% N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), and/or a mixture thereof.
20. The injectable liquid formulation of claim 1 :
wherein the component a) constitutes 20 to 50 wt. % of the total weight of the injectable liquid formulation,
wherein the component a) comprises at least 95% of the at least one triglyceride,
wherein the component b) constitutes 25 to 40 wt. % of the total weight of the injectable liquid formulation, and
wherein the component b) comprises at least 90% N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), and/or a mixture thereof.